The pharmacological strategies currently employed for targeting mutp53 are limited to the use of small molecules (e.g., RITA, PRIMA-1, or NSC59984), which can restore the tumor suppressor function of wild-type p53 of missense-mutp53 proteins [15,16,17]. This evidence concerns the gene TP53 and neoplasm.